Zenas BioPharma (ZBIO) Total Current Liabilities (2023 - 2026)

Zenas BioPharma's Total Current Liabilities history runs 4 years deep, the most recent figure standing at $61.2 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 24.48% year-over-year to $61.2 million in Q1 2026; TTM through Mar 2026 was $61.2 million, a 24.48% increase from a year earlier, with the FY2025 full-year figure at $62.6 million, up 9.35% from the prior year.
• Total Current Liabilities declined to $61.2 million in Q1 2026 per ZBIO's latest filing, from $62.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $62.6 million in Q4 2025 and bottomed at $23.3 million in Q4 2023.
• The 4-year median for Total Current Liabilities is $52.8 million (2025), against an average of $50.4 million.
• Across the five-year window, Total Current Liabilities jumped 146.33% in 2024 and grew 9.35% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $23.3 million in 2023, then soared by 146.33% to $57.3 million in 2024, then grew by 9.35% to $62.6 million in 2025, then fell by 2.38% to $61.2 million in 2026.
• Per Business Quant, the three latest ZBIO Total Current Liabilities figures stand at $61.2 million (Q1 2026), $62.6 million (Q4 2025), and $52.4 million (Q3 2025).